Overview

Webcast ImageWebcast
MannKind at BoAML 2015 Healthcare Conference (Replay)
05/13/15 at 12:00 p.m. PT

MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

Featured Links


Receive E-mail AlertsE-mail Alert Icon
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!
MNKD (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.52
Change (%) Stock is Down 0.11 (2.38%)
Volume3,667,776
Data as of 05/22/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore Press Releases
DateTitle 
05/21/15James S. Shannon Rejoins MannKind's Board of Directors
VALENCIA, Calif., May 21, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that James S. Shannon, MD, MRCP (UK) has been elected to the company's Board of Directors after previously serving as a director from February 2010 until April 2012. The addition of Dr. Shannon brings the total number of MannKind Board members to eight. From May 2012 until his retirement in April 2015, Dr. Shannon was the Chief Medical Officer of GlaxoSmithKline. He formerly held the positio... 
Printer Friendly Version
05/07/15MannKind Corporation Reports 2015 First Quarter Financial Results
- Conference Call at 9:00 AM ET on May 8, 2015 - VALENCIA, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the first quarter ended March 31, 2015. For the first quarter of 2015, total operating expenses were $21.7 million, a decline of 47.5% compared to the similar quarter in 2014. Research and development expenses were $9.4 million, a decline of 64.2% compared to the first quarter of 2014, reflecting the commercialization of A... 
Printer Friendly Version
05/06/15MannKind to Present at Bank of America Merrill Lynch 2015 Healthcare Conference
VALENCIA, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the Bank of America Merrill Lynch 2015 Healthcare Conference on Wednesday, May 13, 2015 at 12:00 pm Pacific Time at the Encore at the Wynn Hotel in Las Vegas, Nevada. Interested parties can access a link to the live webcast of the presentations from the News & Events section ... 
Printer Friendly Version
04/30/15MannKind Corporation to Hold 2015 First Quarter Financial Results Conference Call on May 8, 2015
VALENCIA, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2015 first quarter financial results on Thursday, May 7, 2015 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 9:00 AM (Eastern Time) on May 8, 2015. Presenting from the Company will be its Chief Executive Officer, Hakan Edstrom and Chief Financial Officer, Matthew Pfeffer. To participate in the live call b... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.


Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet